Following on from information provided to NICE by the company in July 2018, the appraisal of Gastric cancer - nivolumab (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1118 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | Bristol-Myers Squibb |
| General commentators | Healthcare Improvement Scotland |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2018, the appraisal of Gastric cancer - nivolumab (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 November 2018 | Suspended. On 27 June 2018, the company notified the Committee of Medicinal Products for Human Use (CHMP) that it was withdrawing its application to extend the license of nivolumab in the treatment of previously treated gastric or gastro-oesophageal junction cancer. Consequently this appraisal has been suspended. We will continue to monitor any developments and will update interested parties if the situation changes. |
| 03 July 2018 | Following an update from the company, the committee meeting scheduled for 19 July 2018 has been postponed. We will provide a further update on the scheduling of this appraisal in due course. |
| 26 April 2018 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the committee discussion will now take place in July 2018. |
| 02 March 2018 | NICE has decided to reschedule this appraisal to align with the company’s latest regulatory expectations. The first committee discussion and will now take place on 22 May 2018. |
| 21 June 2017 | Following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the deadline for submissions is now expected in approximately late November 2017. |
| 05 May 2017 | Invitation to participate |
| 26 January 2017 - 23 February 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual